News – Page 1160 – Endpoints News

SIGN UP

An acquisitive Celgene looks ready to pop a new multiple myeloma deal

9 years ago

Amgen, Novartis celebrate promising migraine data, but Teva and Alder are preparing to crash the party

9 years ago

The gamma delta T cell gambit inspires a small London biotech startup with big ideas

9 years ago

Novavax shares are routed after its big PhIII RSV vaccine trial flops

9 years ago

IPO-bound Intarcia hauls in $215M, and plans to add more; Peloton raises $52M round

9 years ago

Aralez finally gets an FDA OK for its cardio drug Yosprala, starts hiring sales reps

9 years ago

Merck, Pfizer tout PhIII diabetes data as ertuglifozin heads to the FDA

9 years ago

Rigel co-founder, R&D staff jettisoned in the long-awaited lead up to an FDA pitch

9 years ago

Eisai launches biotech division in Massachusetts aimed at Alzheimer’s, I/O and autoimmune diseases

9 years ago

AcelRx takes another step in its recovery program, prepping a pain med pitch to the FDA

9 years ago

Aerie shares rocket up as glaucoma combo drug scores positive data

9 years ago

Agios sets out to raise $150M; AC Immune IPO sets valuation at $700M

9 years ago

The FDA confirms that Sarepta nemesis Ronald Farkas has left the agency

9 years ago

Roche’s megablockbuster MS candidate ocrelizumab posts promising head-to-head data

9 years ago

Atlas partner Saha takes the helm at Delinia, looking to disrupt autoimmune R&D

9 years ago

On a spree, Allergan forks over a big premium to nab Vitae’s autoimmune drugs for $639M

9 years ago

So Takeda wants to do up to $20B in M&A? Welcome to the bidding war for US biotechs

9 years ago

Third Rock ramps up a $57M upstart focusing on proteins in motion

9 years ago

Protocols: RaNA recruits Shire vet as new CSO; Catalent buys Pharmatek

9 years ago

Yale’s David Spiegel inspires another immuno-oncology R&D spinout focused on Antibody Recruiting Molecules

9 years ago

J&J, GSK advance their PhIII IL-6 rheumatoid arthritis drug down to a busy red zone

9 years ago

Captured in a harsh spotlight, biotech unicorn Moderna names Melissa Moore as its new CSO

9 years ago

Tesaro winds up for FDA pitch as PARP rivals race to the finish line

9 years ago

Takeda will transfer 300 staffers to CRO in ongoing R&D overhaul

9 years ago

First page Previous page 1157 1158 115911601161 1162 1163 Next page Last page